Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:
”An 81% 2-year progression-free survival in relapsed multiple myeloma.
Let that sink in.
The phase 3 MonumenTAL-3 trial, published in the NEJM Group , practice changing for patients with relapsed/refractory multiple myeloma.
Key Results
24-month PFS:
- Talquetamab + Daratumumab + Pomalidomide (Tal-DP): 81.3%
- DPd: 51.2%
- HR for progression or death: 0.28
Overall Response Rate:
- 88.2% vs 77.6%
Complete Response or Better:
- 71.1% vs 34.5%
MRD-Negative Complete Response:
- 52.3% vs 15.9%
24-Month Overall Survival:
- 89.2% vs 79.1%
Why this study matters:
Establishes GPRC5D-directed therapy as a major pillar alongside BCMA-targeted approaches.
Congratulations to the patients, investigators, and Johnson and Johnson team on this landmark study.”
Title: Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
Authors: Roberto Mina, Meral Beksac, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos, Jian Li, Philippe Moreau, Yael C. Cohen, Chang-Ki Min, Tomas Jelinek, Jing Christine Ye, Hila Magen, Samuel M. Rubinstein, Weijun Fu, Vania Hungria, Guldane Cengiz Seval, Joao Samuel Farias, Jakub Radocha, Senem Maral, Mehmet Turgut, Youngil Koh, Daniel O’Leary, Jayr Schmidt Filho, Raymond Thertulien, Gang An, Shang-Yi Huang, Sebastian Grosicki, Agata Tyczyńska, Rahul Banerjee, Matthew J. Pianko, Joaquín Martínez-López, Pawel Steckiewicz, Dai Maruyama, Kentaro Fukushima, Albert Oriol, Jordi Lopez Pardo, Hartmut Goldschmidt, Charlotte Pawlyn, Aurore Perrot, Elena Zamagni, Meletios A. Dimopoulos, Leo Rasche, Jaszianne Tolbert, William Terry, Christelle Courtoux, Xiao Liu, Sandra Y. Vasey, Kaitlyn Connors, Mariacristina Festa, Christoph Heuck, Angélique Langlois, Lisa O’Rourke, Jiangxiu Zhou, Xiang Qin, Jiashen Lu, Joy Gong, Diego Vieyra, Peter M. Voorhees
Other Articles Featuring Jad Chahoud On OncoDaily.